Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Authors
Kohei Shitara
National Cancer Center Hospital East, Kashiwa, Japan
Kohei Shitara , Markus H. Moehler , Jaffer A. Ajani , Lin Shen , Marcelo Garrido , Carlos Gallardo , Lucjan S. Wyrwicz , Kensei Yamaguchi , James M. Cleary , Elena Elimova , Ricardo Elias Bruges Maya , Michalis Karamouzis , Tomasz Skoczylas , Arinilda Bragagnoli , Tianshu Liu , Mustapha Tehfe , Kynan Feeney , Rui Wang , Raheel Nathani , Yelena Y. Janjigian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02872116
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 306)
DOI
10.1200/JCO.2024.42.3_suppl.306
Abstract #
306
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
First Author: Yelena Y. Janjigian
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
First Author: Lin Shen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
First Author: Lin Shen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau